BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16185866)

  • 21. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
    Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
    Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
    Wang H; Robl JA; Hamann LG; Simpkins L; Golla R; Li YX; Seethala R; Zvyaga T; Gordon DA; Li JJ
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4146-9. PubMed ID: 21689935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
    Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
    ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
    Wang M
    Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
    Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
    J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors.
    Webster SP; Ward P; Binnie M; Craigie E; McConnell KM; Sooy K; Vinter A; Seckl JR; Walker BR
    Bioorg Med Chem Lett; 2007 May; 17(10):2838-43. PubMed ID: 17350260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
    J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
    Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
    J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitors.
    Yan X; Wang Z; Sudom A; Cardozo M; DeGraffenreid M; Di Y; Fan P; He X; Jaen JC; Labelle M; Liu J; Ma J; McMinn D; Miao S; Sun D; Tang L; Tu H; Ursu S; Walker N; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7071-5. PubMed ID: 20971000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Ganeshapillai D; Smith A; Purohit A; Reed MJ; Potter BV
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):214-7. PubMed ID: 16325333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
    Wu SC; Yoon D; Chin J; van Kirk K; Seethala R; Golla R; He B; Harrity T; Kunselman LK; Morgan NN; Ponticiello RP; Taylor JR; Zebo R; Harper TW; Li W; Wang M; Zhang L; Sleczka BG; Nayeem A; Sheriff S; Camac DM; Morin PE; Everlof JG; Li YX; Ferraro CA; Kieltyka K; Shou W; Vath MB; Zvyaga TA; Gordon DA; Robl JA
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6693-8. PubMed ID: 21983444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1.
    Venier O; Pascal C; Braun A; Namane C; Mougenot P; Crespin O; Pacquet F; Mougenot C; Monseau C; Onofri B; Dadji-Faïhun R; Leger C; Ben-Hassine M; Van-Pham T; Ragot JL; Philippo C; Güssregen S; Engel C; Farjot G; Noah L; Maniani K; Nicolaï E
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2244-51. PubMed ID: 21439819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.
    Yeh VS; Patel JR; Yong H; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Beno D; Brune M; Jacobson P; Sham H; Link JT
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5414-9. PubMed ID: 16899366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.